Zydus Cadila gets final nod from USFDA for Mesalamine tablets
Source: IRIS | 25 Jul, 2017, 01.14PM
|
|
|
|
|
| Rating: NAN / 5 stars. |
 Comments | Post Comment |
|
 Zydus Cadila has received the final approval from the USFDA for Mesalamine Delayed-Release Tablets in the strength of 800 mg. The drug will be manufactured at the group's formulation manufacturing facility at Moraiya.
 The group has received 27 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of the company gained Rs 13.15, or 2.47%, to trade at Rs 544.80. The total volume of shares traded was 153,986 at the BSE (1.03 p.m., Tuesday).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
